AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20729253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference trial (CARPET1)
Number of subjects: 16
Study 20729253 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruiting clinician's opinion
Number of subjects: 16
Study 20729253 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon preference
Number of subjects: 16
Study 17507743 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHOL; 8.4 g x kg(‐1) x d(‐1) carbohydrate)
Number of subjects: 9
Study 17507743 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (NORM; 5.2 g x kg(‐1) x d(‐1) carbohydrate)
Number of subjects: 9
Study 17507743 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (NORM) in midfollicular (MF) phase
Number of subjects: 9
Study 17507743 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHOL) in midfollicular (MF) phase
Number of subjects: 9
Study 17507743 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate loading (CHOL) in midluteal (ML) phase
Number of subjects: 9
Study 17507743 — intervention group
Group type: COMPARATOR
Intervention: Normal diet (NORM) in midluteal (ML) phase
Number of subjects: 9
Study 16268966 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg nocte
Number of subjects: 17
Study 16268966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12766604 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplant patients
Number of subjects: 121
Study 12766604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without criteria of glomerular hyperfiltration
Number of subjects: 121
Study 12766604 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with glomerular hyperfiltration criteria
Number of subjects: 121
Study 10327196 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking (LEG)
Number of subjects: 8
Study 10327196 — intervention group
Group type: EXPERIMENTAL
Intervention: Propelling on a wheelchair (ARM)
Number of subjects: 8
Study 10327196 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbally ordering a second person pushing the wheelchair (VERB)
Number of subjects: 8
Study 8983335 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (24 h treatment)
Number of subjects: 17
Study 8983335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (24 h treatment)
Number of subjects: 17
Study 8983335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (24 h treatment)
Number of subjects: 17
Study 2054534 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonic water plus vodka (approximately 0.05% blood alcohol level)
Number of subjects: 40
Study 2054534 — intervention group
Group type: COMPARATOR
Intervention: Tonic water only
Number of subjects: 40
Study 6295985 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiovarian antiserum, colloidal P-32, delayed split whole abdominal irradiation, and maintenance melphalan
Number of subjects: 49
Study 6295985 — intervention group
Group type: COMPARATOR
Intervention: Intraperitoneal antiserum and multiagent chemotherapy
Number of subjects: 49
Study 6540685 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine and cisplatin
Number of subjects: 105
Study 6540685 — intervention group
Group type: COMPARATOR
Intervention: Vindesine alone
Number of subjects: 105
Study 30805853 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient Families program
Number of subjects: 1826
Study 30805853 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1826
Study 25545117 — intervention group
Group type: EXPERIMENTAL
Intervention: High-income group (>$80K)
Number of subjects: 320
Study 25545117 — intervention group
Group type: COMPARATOR
Intervention: Moderate-income group ($40-80K)
Number of subjects: 320
Study 25545117 — intervention group
Group type: COMPARATOR
Intervention: Low-income group (<$40K)
Number of subjects: 320
Study 25231803 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Walking program (PW)
Number of subjects: 37
Study 25231803 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 37
Study 22305828 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional drug-eluting stent (DES)
Number of subjects: 2400
Study 22305828 — intervention group
Group type: EXPERIMENTAL
Intervention: DES with biodegradable polymer
Number of subjects: 2400
Study 22305828 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS) with biocompatible coating
Number of subjects: 2400
Study 22305828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel-based antiplatelet therapy for 12 months
Number of subjects: 2400
Study 22305828 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel-based antiplatelet therapy for 1 month (in stable patients with BMS)
Number of subjects: 2400
Study 22305828 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary endpoints include stent thrombosis and major bleeding
Number of subjects: 2400
Study 20226286 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 150 mg/month
Number of subjects: 93
Study 17668972 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated flosser (A)
Number of subjects: 102
Study 17668972 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual floss (M)
Number of subjects: 102
Study 17668972 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 102
Study 15814983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooling first-catch urine (FCU) specimens using Roche Amplicor PCR for C. trachomatis and N. gonorrhoeae
Number of subjects: 690
Study 15814983 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooling first-catch urine (FCU) specimens
Number of subjects: 690
Study 15814983 — intervention group
Group type: COMPARATOR
Intervention: Individual testing of FCU specimens
Number of subjects: 690
Study 14571283 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A: 2 x 500 mg paracetamol tablets (Laboratorios Belmac S.A.)
Number of subjects: 12
Study 14571283 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B: 1 x 1,000 mg paracetamol powder sachets (Laboratorios Belmac, S.A.)
Number of subjects: 12
Study 14571283 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C: 2 x 500 mg paracetamol film-coated tablets (Panadol, SmithKline Beecham)
Number of subjects: 12
Study 14571283 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation D: 2 x 500 mg paracetamol tablets (Tylenol, McNeil)
Number of subjects: 12
Study 14571283 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation E: 1 x 1,000 mg effervescent paracetamol tablets (Efferalgan, UPSA)
Number of subjects: 12
Study 10645700 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac + Pitofenone + Fenpiverinium (Manyana)
Number of subjects: 200
Study 10645700 — intervention group
Group type: COMPARATOR
Intervention: Analgin + Pitofenone + Fenpiverinium (Baralgan)
Number of subjects: 200
Study 8911223 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 30
Study 8911223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1872429 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple nerve block (three in one block) with subcostal nerve block
Number of subjects: 50
Study 1872429 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia combined with opioid supplementation
Number of subjects: 50
Study 6347752 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 200 mg b.i.d.
Number of subjects: 8
Study 6347752 — intervention group
Group type: COMPARATOR
Intervention: Verapamil 120 mg t.i.d.
Number of subjects: 8
Study 31596819 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-based models (Model 4 with NLP 5-grams)
Number of subjects: 372
Study 31596819 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-based models (Model 7, combination of Models 1 and 4)
Number of subjects: 372
Study 31596819 — intervention group
Group type: COMPARATOR
Intervention: Administrative data only (Model 1)
Number of subjects: 372
Study 31596819 — intervention group
Group type: EXPERIMENTAL
Intervention: NLP-based models
Number of subjects: 372
Study 28845898 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine ER 75-mg capsule before RYGB
Number of subjects: 10
Study 28845898 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75-mg capsule after RYGB
Number of subjects: 10
Study 25656305 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2409021 (5, 30, 60 or 90mg) administered daily for 28 days to patients with type 2 diabetes
Number of subjects: 79
Study 25656305 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2409021 (single doses)
Number of subjects: 79
Study 25656305 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2409021 (multiple dosing)
Number of subjects: 79
Study 24347519 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin-docetaxel-capecitabine (EDC)
Number of subjects: 536
Study 22869576 — intervention group
Group type: EXPERIMENTAL
Intervention: mericitabine plus danoprevir
Number of subjects: 73
Study 19534829 — intervention group
Group type: EXPERIMENTAL
Intervention: RTP‐ASE Qontrast quantification
Number of subjects: 67
Study 19534829 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual evaluation of ischaemia
Number of subjects: 67
Study 19534829 — intervention group
Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 67
Study 17325311 — intervention group
Group type: EXPERIMENTAL
Intervention: Empower Youth Program (9-week intervention)
Number of subjects: 40
Study 17325311 — intervention group
Group type: COMPARATOR
Intervention: Usual school services
Number of subjects: 40
Study 15611894 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder‐head elevation pillow (SHEP)
Number of subjects: 14
Study 15611894 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP) therapy
Number of subjects: 14
Study 11586699 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (ivadal) 10 mg once daily before sleep for 2 weeks
Number of subjects: 1017
Study 10340198 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h behavioural skills building intervention focused on educating women about the female condom, motivating use, and building relevant skills.
Number of subjects: 105
Study 10340198 — intervention group
Group type: COMPARATOR
Intervention: Time-matched broadly defined women's health education intervention.
Number of subjects: 105
Study 10340198 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐h behavioural skills building intervention
Number of subjects: 105
Study 8938533 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunodeficient patients
Number of subjects: 13
Study 8938533 — intervention group
Group type: COMPARATOR
Intervention: Immunocompetent patients
Number of subjects: 13
Study 8938533 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute infection (immunodeficient)
Number of subjects: 13
Study 8938533 — intervention group
Group type: COMPARATOR
Intervention: Chronic infection (immunocompetent)
Number of subjects: 13
Study 8938533 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic infection (immunodeficient)
Number of subjects: 13
Study 1927064 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms twice daily after meals
Number of subjects: 0
Study 1927064 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1927064 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 1927064 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID treatment
Number of subjects: 0
Study 6802080 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine
Number of subjects: 0
Study 6802080 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 0
Study 31860407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoids (IVGCs)
Number of subjects: 99
Study 31860407 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucocorticoids (OGCs)
Number of subjects: 99
Study 31860407 — intervention group
Group type: COMPARATOR
Intervention: Control group (no steroids)
Number of subjects: 99
Study 30572941 — intervention group
Group type: EXPERIMENTAL
Intervention: mhGAP-based training
Number of subjects: 18
Study 26581718 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.7 mg
Number of subjects: 0
Study 26581718 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX implant 0.35 mg
Number of subjects: 0
Study 26581718 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 24989138 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tedizolid phosphate 100-400 mg
Number of subjects: 90
Study 24989138 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tedizolid phosphate 200 mg once/day for 7 days
Number of subjects: 90
Study 24989138 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of tedizolid phosphate 200 mg
Number of subjects: 90
Study 24989138 — intervention group
Group type: COMPARATOR
Intervention: IV tedizolid phosphate 200 mg
Number of subjects: 90
Study 24989138 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 90
Study 22030442 — intervention group
Group type: EXPERIMENTAL
Intervention: Purposeful activity group (PA-group, n=15)
Number of subjects: 30
Study 22030442 — intervention group
Group type: COMPARATOR
Intervention: Rote exercises group (Rex-group, n=15)
Number of subjects: 30
Study 20113145 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient appliance therapy
Number of subjects: 73
Study 20113145 — intervention group
Group type: COMPARATOR
Intervention: Non-occluding control appliance
Number of subjects: 73
Study 17976724 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (0.5 mg) administered over a 2-year period
Number of subjects: 0
Study 17976724 — intervention group
Group type: EXPERIMENTAL
Intervention: First-eye model of ranibizumab treatment
Number of subjects: 0
Study 17976724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined model of ranibizumab treatment
Number of subjects: 0
Study 15990632 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy density feeds (oil added; caloric density = 35 kcal/100 g)
Number of subjects: 20
Study 15990632 — intervention group
Group type: COMPARATOR
Intervention: Low energy density feeds (without oil; caloric density = 20 kcal/100 g)
Number of subjects: 20
Study 12898763 — intervention group
Group type: EXPERIMENTAL
Intervention: ProFile nickel‐titanium rotary instruments
Number of subjects: 95
Study 12898763 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel hand files‐FlexoFile
Number of subjects: 95
Study 10097838 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (10 sessions)
Number of subjects: 86
Study 10097838 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy (10 sessions)
Number of subjects: 86
Study 10097838 — intervention group
Group type: COMPARATOR
Intervention: Both modalities
Number of subjects: 86
Study 8835624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atropine (0.03 mg/kg i.v.)
Number of subjects: 9
Study 8835624 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (10-15 mg i.v.)
Number of subjects: 9
Study 8835624 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo condition)
Number of subjects: 9
Study 1596811 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic treatment (thuya 30 CH, antimonium crudum 7 CH, nitricum acidum 7 CH)
Number of subjects: 162
Study 1596811 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 162
Study 6586395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical PGE2 gel
Number of subjects: 41
Study 6586395 — intervention group
Group type: COMPARATOR
Intervention: Intraamniotic PGF(2a)
Number of subjects: 41
Study 30327868 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberry drink (WBB)
Number of subjects: 54
Study 30327868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 29506072 — intervention group
Group type: EXPERIMENTAL
Intervention: IPV/RC communication-skills building workshop
Number of subjects: 679
Study 29506072 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard knowledge-based IPV/RC training
Number of subjects: 679
Study 29506072 — intervention group
Group type: COMPARATOR
Intervention: Historical controls
Number of subjects: 679
Study 26906970 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone website
Number of subjects: 161
Study 26906970 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 161
Study 24952700 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient supplementation
Number of subjects: 74
Study 24952700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim
Number of subjects: 16
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg iptakalim
Number of subjects: 16
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iptakalim
Number of subjects: 16
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim (women)
Number of subjects: 16
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg iptakalim (women)
Number of subjects: 16
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim (men)
Number of subjects: 16
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg iptakalim (fasting and nonfasting)
Number of subjects: 16
Study 22309265 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg, 10 mg, 20 mg iptakalim
Number of subjects: 16
Study 20077478 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 hours of clinic group rehabilitation plus 9 hours of attention control social sessions
Number of subjects: 116
Study 20077478 — intervention group
Group type: EXPERIMENTAL
Intervention: 27 hours of rehabilitation (18 in clinic group rehabilitation and 9 hours designed for home and community routines)
Number of subjects: 116
Study 20077478 — intervention group
Group type: COMPARATOR
Intervention: 0 hours of rehabilitation
Number of subjects: 116
Study 17822876 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus treatment
Number of subjects: 11
Study 15641091 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 21
Study 15641091 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 21
Study 12704675 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing)
Number of subjects: 14349
Study 12704675 — intervention group
Group type: COMPARATOR
Intervention: Control arm (PSA testing)
Number of subjects: 14349
Study 10568897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size calculations based on statistical power for testing hypotheses
Number of subjects: 0
Study 10568897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size methods based on ensuring accurate estimation of important parameters
Number of subjects: 0
Study 10568897 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods and examples for sample size calculations for continuous and dichotomous outcomes
Number of subjects: 0
Study 8740602 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive self-hypnosis (CSH) treatment
Number of subjects: 144
Study 8740602 — intervention group
Group type: COMPARATOR
Intervention: Autogenic training (AT)
Number of subjects: 144
Study 8500238 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 743
Study 8500238 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine-isosorbide dinitrate
Number of subjects: 743
Study 3481557 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of tumor markers (carcinoembryonic antigen, ferritin, cancer antigen 125, tissue polypeptide antigen)
Number of subjects: 109
Study 3481557 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated characteristic value (greater than or equal to cut-off score)
Number of subjects: 109
Study 3481557 — intervention group
Group type: COMPARATOR
Intervention: Normal tumor marker profiles
Number of subjects: 109
Study 30849021 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention (7-week class on health behaviors)
Number of subjects: 532
Study 30849021 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention
Number of subjects: 532
Study 30849021 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 532
Study 28914592 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% HA gel
Number of subjects: 36
Study 28914592 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8% HA gel
Number of subjects: 36
Study 28914592 — intervention group
Group type: COMPARATOR
Intervention: Control group (periodontal dressing only)
Number of subjects: 36
Study 27085637 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network-based intervention promoting water consumption (n=106)
Number of subjects: 210
Study 27085637 — intervention group
Group type: COMPARATOR
Intervention: Control condition (n=104)
Number of subjects: 210
Study 25468576 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal 0.25% levobupivacaine (Group L(0.25))
Number of subjects: 212
Study 25468576 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal 0.20% levobupivacaine (Group L(0.20))
Number of subjects: 212
Study 25468576 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal 0.20% levobupivacaine plus 2 μg/kg dexmedetomidine (Group LD)
Number of subjects: 212
Study 24041817 — intervention group
Group type: EXPERIMENTAL
Intervention: Former IDA children
Number of subjects: 47
Study 24041817 — intervention group
Group type: COMPARATOR
Intervention: Non-anemic children
Number of subjects: 47
Study 22289528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of celecoxib and FOLFOX4 regimen (folinic acid‐fluorouracil‐oxaliplatin)
Number of subjects: 90
Study 22289528 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX4 regimen alone
Number of subjects: 90
Study 19358502 — intervention group
Group type: EXPERIMENTAL
Intervention: Herb-partitioned moxibustion combined with amitriptyline
Number of subjects: 60
Study 19358502 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline alone
Number of subjects: 60
Study 16638737 — intervention group
Group type: EXPERIMENTAL
Intervention: CS‐706 (2‐ to 800‐mg doses daily, up to 14 days)
Number of subjects: 130
Study 15580062 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml meal rich in fat
Number of subjects: 20